Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

Exclusion Criteria

• •Criteria by which patients are not included in the study
• •Platinum-sensitive relapse of ovarian cancer (disease recurrence occurred more than 6 months after the last administration of platinum drugs).
• •Presence of serious diseases or health conditions:
• •1. Other malignancies, with the exception of malignancies treated more than 5 years ago without signs of return of the disease.
• •2. Brain metastases or leptomeningeal metastases.
• •3. Active infection (e.g. fever ≥38 °C), including active or unresolved pneumonia/pneumonitis.
• •4. Uncontrolled diabetes mellitus.
• •5. Myocardial Infarction in the last 12 months, severe/unstable angina, clinically manifested heart failure class III-IV according to the classification of the New York Cardiology Association (NYCA).
• •6. Gastrointestinal bleeding within the last 2 weeks.
• •7. Human immunodeficiency virus (HIV), chronic or acute hepatitis B or hepatitis C.
• •8. Patients with autoimmune disorders or organ transplantation who require immunosuppressive therapy.
• •I. Mental illness that may increase the risk associated with participation in the study or taking the study drug or that may affect the interpretation of the results of the study.
• •K. Polyallergy, bronchial asthma (including aspirin) in history.
• •Major surgery during the previous 4 weeks (complete wound healing).
• •Previous chemotherapeutic treatment of the patient according to the scheme GEMCITABINE
• •Radiotherapy with extended field radiation within the previous 4 weeks or radiotherapy with a limited field radiation within the previous 2 weeks.